Skip to main content

Table 1 Canakinumab doses by phenotypes

From: Dosing patterns of canakinumab in patients with Cryopyrin-Associated Periodic Syndromes (CAPS): A comparative analysis of a study in Western versus Japanese patients

Phenotype (n=WP/JP) Wester population Japanese population
  Adult1 Mean/median (mg) (N=136) Pediatrics2 Mean/mdeian (mg/kg) (N=29) Adult1 Mean/median (mg) (N=8) Pediatrics2 Mean/mdeian (mg/kg) (N=11)
MWS (103/7) 200/150 5.5/4.0 225/150 6.0/6.0
NOMID (32/11) 299/150 5.8/4.0 300/225 5.5/6.0
FCAS (30/0) 189/150 2.7/2.0 - -